AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28838473
Drug: Polymer-free biolimus
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymer-free biolimus A9 drug-coated stents (DCS)
Trial: 14738771
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of upright and inverted face processing
Trial: 11092071
Drug: Regular substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular substance abuse treatment programs
Trial: 3102303
Drug: Best oral
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best oral feeding
Trial: 29653635
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g omega-3 FA daily
Trial: 28281457
Drug: Sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg/day
Trial: 23717490
Drug: BMS-936558 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-936558 (0.1 mg/kg or 10 mg/kg)
Trial: 23717490
Drug: BMS-936558 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-936558 (10 mg/kg)
Trial: 8661976
Drug: Intranasal synthetic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal synthetic SCT (200 IU daily)
Trial: 8661976
Drug: Thrice-weekly calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly calcitonin
Trial: 1804669
Drug: Almitrine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine (100 mg.day-1, intermittent schedule)
Trial: 6289963
Drug: Ceftriaxone 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 62.5 mg
Trial: 6289963
Drug: Ceftriaxone 32.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 32.5 mg
Trial: 6289963
Drug: Kanamycin 2
RxNorm normalized name: kanamycin 250 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kanamycin 2 g
Trial: 25855073
Drug: Postoperative drug
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative drug therapy to prevent disease recurrence
Trial: 23980084
Drug: Brivanib 800
RxNorm normalized name: Brivanib
DrugBank: Brivanib (DB11958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib 800 mg once daily orally
Trial: 23980084
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg twice daily orally
Trial: 11055474
Drug: Candesartan cilexetil/hydrochlorothiazide
RxNorm normalized name: Candesartan Cilexetil/Hydrochlorothiazide 32 MG-25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan cilexetil/hydrochlorothiazide (candesartan/HCT; 16/12.5 mg)
Trial: 11055474
Drug: Losartan/hydrochlorothiazide (losartan/HCT;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan/hydrochlorothiazide (losartan/HCT; 50/12.5 mg)
Trial: 8379551
Drug: Cognitive-behavioral program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral program (10 weeks of group therapy)
Trial: 8379551
Drug: Slow taper
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow taper condition alone
Trial: 2875594
Drug: Fentanyl 0.1
RxNorm normalized name: fentanyl 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.1 mg-droperidol 5 mg
Trial: 29665102
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of broad-spectrum antibiotics followed by FMT from a donor enriched in Lachnospiraceae and Ruminococcaceae
Trial: 29665102
Drug: Standard-of-care (SOC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SOC, no antibiotics/FMT)
Trial: 16181465
Drug: 5% 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% 5-fluorouracil (5-FU) cream applied twice daily for 3 weeks
Trial: 16181465
Drug: 5% 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% 5-fluorouracil (5-FU) cream applied twice daily for 1 day per week for 12 weeks
Trial: 12680810
Drug: Treatment 2
RxNorm normalized name: epoch Blemish Treatment 2 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 2 (T2) - Communicative Reading Strategies (CRS)
Trial: 12680810
Drug: Treatment 1
RxNorm normalized name: CVS Acne Treatment 10% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 1 (T1) - Traditional decoding‐based feedback strategies
Trial: 10686664
Drug: L-carnitine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (3 x 1 g daily for 120 days)
Trial: 8836270
Drug: Propofol (15-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (15-20 mg/kg.h) with 30% O2 in air
Trial: 8836270
Drug: Propofol (10-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (10-15 mg/kg.h) with 30% O2 in N2O
Trial: 1364936
Drug: Plain naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain naproxen tablets (PT)
Trial: 22954919
Drug: Multi-frequency low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Multi-frequency low-dose intravenous iron (iron sucrose 25 mg, twice a week for 8 weeks)
Trial: 22954919
Drug: Less-frequency regular-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less-frequency regular-dose intravenous iron (iron sucrose 100 mg, once every two weeks for 8 weeks)
Trial: 12401757
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (RSG) 4 mg b.i.d.
Trial: 12401757
Drug: Glyburide (GLB)
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide (GLB) titrated to mean 10.5 mg/day for the first 8 weeks
Trial: 10350385
Drug: Cefepime 2
RxNorm normalized name: cefepime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 2 g every 12 h for a minimum of 3 days and up to 14 days
Trial: 10350385
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g every 12 h for a minimum of 3 days and up to 14 days
Trial: 9166486
Drug: Conventional supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional supportive treatment alone
Trial: 1613829
Drug: 0.2 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg/day rhGH
Trial: 27893130
Drug: Inpatient palliative
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient palliative care (n=81), seen by palliative care clinicians at least twice a week during HCT hospitalization.
Trial: 20208067
Drug: Individual characteristics
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual characteristics (e.g., choice of general practitioner, male gender, age)
Trial: 17389624
Drug: Enoxaparin (0.67
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (0.67 +/- 0.14 mg/kg)
Trial: 17389624
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin (UFH, bolus of 1500 IU followed by infusion of 2750 IU)
Trial: 15549327
Drug: 5-FU 450
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 450 mg/m2 and leucovorin 100 mg/m2 x 5 days every 4 weeks; six cycles (arm A)
Trial: 15549327
Drug: 24-h infusion
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-h infusion of high-dose 5-FU/leucovorin 2,600 mg/m2 and 500 mg/m2, two cycles of six applications (arm B)
Trial: 15549327
Drug: 24-h infusion
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-h infusion of high-dose 5-FU 2,600 mg/m2, two cycles of six applications (arm C)
Trial: 9928771
Drug: Analgesic treatment
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic treatment (non-opioid or opioid analgesics, antidepressants, anticonvulsants, corticosteroids)
Trial: 9928771
Drug: Palliative antineoplastic
RxNorm normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Palliative antineoplastic treatment
Trial: 28601567
Drug: All evidence-based
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All evidence-based measures (prophylactic antibiotics within 60 minutes of cesarean delivery, chlorhexidine-alcohol for skin antisepsis, closure of subcutaneous layer if ≥2 cm, subcuticular skin closure with suture)
Trial: 17937565
Drug: Dietary soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary soy supplements (part of a randomized, placebo-controlled trial)
Trial: 15743397
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone (200 mg over a 3 h period)
Trial: 11990732
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (ND) 200 mg/week, intramuscularly for 8 weeks
Trial: 9655532
Drug: Azithromycin (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (oral, for 5 days)
Trial: 9655532
Drug: Placebo (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral, for 5 days)
Trial: 7653817
Drug: 3‐in‐1 block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐in‐1 block with 40 mL of 1.5% lidocaine plus epinephrine (n = 13)
Trial: 7653817
Drug: 3‐in‐1 block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐in‐1 block with 50 mL of 1.5% lidocaine plus epinephrine (n = 11)
Trial: 7653817
Drug: Direct obturator
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct obturator nerve block with 10 mL of 2% lidocaine plus epinephrine (n = 20)
Trial: 2683439
Drug: Continuous application
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous application of 0.1% fluprednidene-21-acetate twice a day
Trial: 2683439
Drug: Intermittent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent therapy with 1 day intermission (15 patients)
Trial: 2683439
Drug: Intermittent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent therapy with 2 days intermission (16 patients)
Trial: 2683439
Drug: Intermittent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent therapy with 3 days intermission (13 patients)
Trial: 2683439
Drug: Fluprednidene treatment
RxNorm normalized name: fluprednidene
DrugBank: Fluprednidene acetate (DB14634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluprednidene treatment in eczema patients
Trial: 335225
Drug: Combined calcium
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined calcium and vitamin D‐2 phosphate treatment
Trial: 335225
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and phosphate treatment
Trial: 31399438
Drug: Liraglutide (≤1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (≤1.8 mg daily; n = 4,668)
Trial: 26348751
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of elemental iron (as ferrous fumarate)
Trial: 22684652
Drug: Micronutrient cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient cocktail containing physiological doses of antioxidant vitamins and trace minerals
Trial: 17107402
Drug: Desloratadine 5
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5 mg plus montelukast 10 mg
Trial: 17107402
Drug: Desloratadine 5
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5 mg plus placebo
Trial: 15174894
Drug: Oral modified-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral modified-release clarithromycin 500 mg/day for 3 months
Trial: 9248762
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP-DH) cortisol suppression 12-24 h after last dose
Trial: 9248762
Drug: Budesonide (BUD-TBH)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BUD-TBH) cortisol suppression 12-24 h after last dose
Trial: 24188897
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (100mg elemental Zn daily for 60 days)
Trial: 20846599
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg maintenance dose (MD)
Trial: 20846599
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg maintenance dose (MD)
Trial: 20846599
Drug: Prasugrel 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 60 mg loading dose (LD) + 10 mg maintenance dose (MD)
Trial: 20846599
Drug: Prasugrel loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel loading dose (LD)
Trial: 18718780
Drug: Subantimicrobial doses
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subantimicrobial doses of doxycycline for 6 months
Trial: 3772891
Drug: Single perioperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single perioperative dose of mezlocillin
Trial: 3772891
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of mezlocillin
Trial: 3772891
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of cefoxitin
Trial: 26832658
Drug: IAI 2
RxNorm normalized name: Intravitreal aflibercept injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAI 2 mg every 4 weeks (2q4) in patients without prior anti-VEGF treatment
Trial: 26832658
Drug: IAI 2
RxNorm normalized name: Intravitreal aflibercept injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAI 2 mg every 8 weeks after 5 monthly doses (2q8) in patients without prior anti-VEGF treatment
Trial: 26832658
Drug: Macular laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macular laser photocoagulation in patients without prior anti-VEGF treatment
Trial: 23897775
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg every other week for 10 weeks
Trial: 22293719
Drug: 0.1% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% ropivacaine (basal 12 ml/h; bolus 4 ml)
Trial: 22293719
Drug: 0.4% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% ropivacaine (basal 3 ml/h; bolus 1 ml)
Trial: 20598077
Drug: Dalteparin low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin low-molecular-weight heparin (LMWH) 5000 anti-Xa units, subcutaneously once daily for 6 months.
Trial: 20598077
Drug: Placebo, subcutaneously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, subcutaneously once daily for 6 months.
Trial: 20598077
Drug: Dalteparin low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin low-molecular-weight heparin (LMWH) 5000 anti-Xa units.
Trial: 17637403
Drug: Postdischarge enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postdischarge enoxaparin (40 mg once daily for 20 days)
Trial: 17637403
Drug: Placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once daily for 20 days)
Trial: 17637403
Drug: Postdischarge enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postdischarge enoxaparin (40 mg once daily)
Trial: 15310644
Drug: NOBLOCK group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOBLOCK group (no neuromuscular blocking agent)
Trial: 9661545
Drug: Preemptive epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive epidural bupivacaine (0.66 mL/kg 0.25%) with morphine (0.02 mg/kg) administered caudally before surgery
Trial: 9661545
Drug: Postincisional administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postincisional administration of the same bupivacaine-morphine mixture after surgery
Trial: 9661545
Drug: Preemptive epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive epidural bupivacaine with morphine
Trial: 9661545
Drug: Postincisional administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postincisional administration of the same bupivacaine-morphine mixture
Trial: 7714226
Drug: Nefazodone 100
RxNorm normalized name: NEFAZODONE 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone 100 mg twice daily
Trial: 7714226
Drug: Nefazodone 200
RxNorm normalized name: NEFAZODONE 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone 200 mg twice daily
Trial: 7714226
Drug: Imipramine 50
RxNorm normalized name: trimipramine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 50 mg twice daily
Trial: 2757895
Drug: Alpha-interferon (Roferon-A)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpha-interferon (Roferon-A) administered as an intra-muscular injection (3 x 10(6) iu) once-a-day over 3 days
Trial: 54852
Drug: Gelatin infusion
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin infusion
Trial: 54852
Drug: Dextran 60
RxNorm normalized name: dextran 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran 60 infusion
Trial: 27894985
Drug: Co-infected cases
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-infected cases receiving antiretroviral therapy (ART)
Trial: 11686419
Drug: Low-dose inhaled
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose inhaled fluticasone propionate (FP) 44 microg, two puffs twice daily for 4 weeks
Trial: 11686419
Drug: Oral zafirlukast
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral zafirlukast (ZK) 20 mg, twice daily for 4 weeks
Trial: 11301564
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir 1,000 mg every 3 hours (six times a day)
Trial: 11301564
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir 1,000 mg four times a day
Trial: 11301564
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir 1,000 mg three times a day
Trial: 11301564
Drug: Single 5-mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 5-mg/kg intravenous infusion of ganciclovir
Trial: 11301564
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir 6,000 mg/day
Trial: 11301564
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir 3,000 mg/day and 4,000 mg/day
Trial: 11301564
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir 4,000 mg/day and 6,000 mg/day
Trial: 3062257
Drug: OPA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPA therapy (2 cycles) for stage I/IIA
Trial: 3062257
Drug: OPA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPA therapy (2 cycles) and COMP therapy (2 cycles) for stage IIB/IIIA
Trial: 3062257
Drug: OPA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPA therapy (2 cycles) and COMP therapy (4 cycles) for stage IIIB/IV
Trial: 3062257
Drug: Radiotherapy (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy (dosage of 35, 30 or 25 Gy depending on chemotherapy extent)
Trial: 26147010
Drug: P2G12 (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P2G12 (monoclonal antibody derived from transgenic tobacco)
Trial: 23453465
Drug: Lateral position
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral position (Group L)
Trial: 20034685
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg/d + Atorvastatin 10 mg
Trial: 16918659
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg x kg(‐1) of ketamine before surgery (Group II)